SASTASUNDR2024-01-012024-03-31 SASTASUNDR2024-01-012024-03-31 SASTASUNDR2024-01-012024-03-31in-bse-fin:OneOtherRevenueFromOperations01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourOtherRevenueFromOperations01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member SASTASUNDR2024-03-31 SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member SASTASUNDR2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member SASTASUNDR2024-03-31 SASTASUNDR2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member SASTASUNDR2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member SASTASUNDR2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SASTASUNDR2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 533259 SASTASUNDR NOTLISTED Sastasundar Ventures Limited Equity 2023-04-01 2024-03-31 2024-05-30 2024-05-21 INR Lakhs Yearly 2024-05-30 15:45:00 2024-05-30 20:30:00 true Cash Flow Indirect Statement on impact of audit qualification Multi segment 2024-01-01 2024-03-31 Audited Consolidated 1719000.00 506000.00 0.00 0.00 38693000.00 0.00 3016296000.00 8353000.00 1136000.00 3066703000.00 184635000.00 3251338000.00 4311000.00 2509894000.00 302226000.00 119370000.00 2748000.00 25278000.00 0.00 0.00 0.00 0.00 237400000.00 3201227000.00 50111000.00 0.00 50111000.00 -225948000.00 -66213000.00 -292161000.00 342272000.00 0.00 0.00 0.00 -126555000.00 215717000.00 1735000.00 217452000.00 164355000.00 51362000.00 165892000.00 51560000.00 318105000.00 10 5.17 5.17 0.00 0.00 5.17 5.17 0.00 0.00 0.00 1. The above Audited Consolidated Financial Results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 30th May, 2024. The Consolidated financial results for the year ended March 31, 2024 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. 3. During the previous year, the Board of Directors at its meeting held on 27th March, 2023 approved a Composite Scheme of Arrangement (the Scheme) for Demerger and Amalgamation amongst Sastasundar Ventures Limited (‘Demerged Company’ or ‘Amalgamated Company’) and Microsec Resources Private Limited (“Resulting Company”) and Sastasundar Healthbuddy Limited (“Amalgamating Company”) under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013 and the rules made there under, with effect from 1st April, 2023 (the Appointed Date). Upon receipt of requisite approvals of the concerned regulatory authorities, the scheme will be recognised in the financial results. As per the provisions of paragraph 3(b) of Part 1(A) of the SEBI Master Circular dated June 20, 2023, the Amalgamated company (post Amalgamation) is required to maintain pre-public shareholding of minimum 25% including QIB of Amalgamating Company. As a part of the process, the company has filed an application with Securities and Exchange Board of India (SEBI) seeking exemption from the aforesaid provision of SEBI Master Circular dated June 20, 2023, for consideration of Mitsubishi Corporation, Japan and Rohto Pharmaceuticals Company Limited, Japan, the public shareholder of Amalgamating Company as public shareholders of Amalgamated Company. We hereby inform that SEBI vide letter dated January 30, 2024 has informed the company that the competent authority has not acceded the company’s request. The Designated Stock Exchange has not granted approval to the Scheme. The Company is exploring for appropriate steps in this regard for further course of action. 4. The Board of Directors at its meeting held on 21st March, 2024 approved a Scheme of Arrangement (the Scheme) for amalgamation of Retailer Shakti Supply Chain Private Limited (Transferor Company) (the Step down Subsidiary) with Sastasundar Healthbuddy Limited (“Transferee Company”) (subsidiary Company) under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013 and the rules made there under, with effect from 1st April, 2023 (the Appointed Date). The Scheme is subject to requisite approvals of the concerned regulatory authorities. Pending such approvals, the scheme has not been recognised in these financial statements. 5. Exceptional items represent the gain on following transaction/ event: During the previous year, the management based on its internal assessment, has detected misappropriation of cash collections from customers aggregating to Rs. 796.45 lakhs (Sastasundar Healthbuddy Limited- Rs. 161.40 Lakhs) (Retailer Shakti Supply Chain Pvt Ltd- Rs. 635.05 Lakhs) by few employees of the Sastasundar Healthbuddy Limited (“SHBL”), subsidiary of the company and Retailer Shakti Supply Chain Pvt Ltd (RSCPL), step down subsidiary of the company. SHBL has referred the matter to the police department and after filing of the First Information Report (FIR), the aforesaid employees were arrested by the police and an investigation charge sheet has been filed with the Additional Chief Judicial Magistrate, Baruipur, West Bengal by the police. SHBL and RSCPL has expensed the aforesaid amount during the previous year under the heading “exceptional item”. Multi segment 2023-04-01 2024-03-31 Audited Consolidated 7065000.00 1968000.00 0.00 0.00 196386000.00 0.00 13517285000.00 30282000.00 4107000.00 13757093000.00 604104000.00 14361197000.00 19507000.00 11676304000.00 631965000.00 490170000.00 10092000.00 91379000.00 0.00 0.00 0.00 0.00 884992000.00 13804409000.00 556788000.00 0.00 556788000.00 -127557000.00 -235953000.00 -363510000.00 920298000.00 0.00 0.00 0.00 -861772000.00 58526000.00 1172000.00 59698000.00 88827000.00 -30301000.00 89741000.00 -30043000.00 318105000.00 10 2.79 2.79 0.00 0.00 2.79 2.79 0.00 0.00 0.00 Other financial income 1136000.00 Other financial income 4107000.00 Other Expenses 237400000.00 Other Expenses 884992000.00 336077000.00 153507000.00 426452000.00 83172000.00 6760658000.00 1103913000.00 8863779000.00 1157947000.00 18877000.00 4053000.00 24492000.00 716054000.00 3500000.00 361434000.00 556000.00 345238000.00 2632151000.00 11495930000.00 318105000.00 7305640000.00 9995342000.00 117469000.00 307910000.00 0.00 220717000.00 646096000.00 25677000.00 54013000.00 676403000.00 98399000.00 854492000.00 11495930000.00 Financial Services 42055000.00 Healthcare Network 3024648000.00 Financial Services 209526000.00 Healthcare Network 13547567000.00 3066703000.00 13757093000.00 0.00 0.00 3066703000.00 13757093000.00 Financial Services 38515000.00 Healthcare Network -156594000.00 Financial Services 189580000.00 Healthcare Network -185609000.00 -118079000.00 3971000.00 2748000.00 10092000.00 -170938000.00 -562909000.00 50111000.00 556788000.00 Financial Services 843300000.00 Healthcare Network 10247742000.00 11091042000.00 404888000.00 11495930000.00 Financial Services 26361000.00 Healthcare Network 1433388000.00 1459749000.00 40839000.00 1500588000.00 2. The Group has identified the following segments : (a) Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. (b) Healthcare Network - includes activities for pathology and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations. 7. Sastasundar Healthbuddy Limited (SHBL) subsidiary of the Company's has received 99,873 number of 0.01% Non-Cumulative Compulsorily Convertible Preference Shares (CCPS) from its associate (erstwhile wholly owned subsidiary) in the earlier financial year. SHBL has entered into a Put Call Option Agreement on 19 November 2021 with its associate and the purchaser (‘the investor’) (the Holding Company of the associate) whereby it agreed to sell 75.1% of the aforesaid CCPS (‘milestone shares’) to the investor at a specified consideration on achievement of certain milestones on or before the milestone event target dates by the Company. The put call option agreement was subsequently amended on 3 March 2022 and 17 April 2023. As per the last amendment, SHBL agreed to transfer 12,612 CCPS to the investor for an agreed consideration, against which Rs. 1,669.23 lakhs was received in May 2023, and 4,182 CCPS to be converted into equity shares of the associate as per the conversion ratio defined in the agreement, post achievement of the specified milestones. With respect to the remaining CCPS, it was decided that SHBL, the associate and the investor will mutually discuss and agree in writing the terms and conditions of the remaining milestone events, milestone shares and milestone consideration. The maximum overall consideration payable for all milestones has been specified by the amendment agreement dated 17 April 2023 which is in line with the amended Put Call Option Agreement dated 3 March 2022. The management, based on its internal assessment and best estimate of milestone events, milestone shares and milestone consideration, has derived the fair value of the investment for the aforesaid CCPS by engaging an independent registered valuer. 8. The figure for the quarter ended 31st March, 2024 and 31st March, 2023 are the balancing figure between audited figure in respect of the full financial year and the unaudited published period to date reviewed figures upto the end of the third quarter 31st December, 2023 and 31st December, 2022 which were subjected to a limited review. 9. Previous Period/ Year figures have been re-grouped / re-classified wherever necessary. Remeasurement gain/ (loss) on defined benefit plans (net of tax) 2581000.00 Remeasurement gain/ (loss) on defined benefit plans (net of tax) 1868000.00 2581000.00 1868000.00 846000.00 696000.00 1735000.00 1172000.00 10092000.00 650371000.00 -111167000.00 0.00 83439000.00 0.00 -3295000.00 -20440000.00 0.00 -141305000.00 0.00 16495000.00 0.00 91379000.00 0.00 -5185000.00 0.00 21123000.00 0.00 0.00 1968000.00 228032000.00 0.00 -327065000.00 0.00 -198502000.00 0.00 49876000.00 0.00 -114184000.00 442604000.00 0.00 0.00 0.00 60951000.00 0.00 381653000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6322000.00 142314000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6972002000.00 8975768000.00 0.00 0.00 0.00 0.00 1968000.00 217377000.00 0.00 1581138000.00 0.00 -339275000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22955000.00 0.00 560000.00 0.00 0.00 -23515000.00 18863000.00 0.00 18863000.00 317214000.00 336077000.00